-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer is cancer that develops from breast tissue
breast cancer
The FDA has expanded the approval of AstraZeneca and Merck & Co.
FDA
The approval was supported by results from the Phase III OlympiA trial, also published in NEJM
Regarding the key secondary objective of overall survival (OS), the results showed that while Lynparza's 3-year estimated OS was higher than placebo, the difference was not significant at the interim analysis
Regarding the key secondary objective of overall survival (OS), the results showed that while Lynparza's 3-year estimated OS was higher than placebo, the difference was not significant at the interim analysis
Lynparza is already approved in the US, EU, Japan and several other countries for patients with gBRCAm, HER2-negative, metastatic breast cancer who have previously received chemotherapy
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5524473 https://firstwordpharma.
com/story/5524473
Leave a comment here